Skip to main content
padlock icon - secure page this page is secure

Serotonin Reuptake Inhibition: An Update on Current Research Strategies

Buy Article:

$68.00 + tax (Refund Policy)

Selective Serotonin reuptake inhibitors (SSRIs) have contributed to the major advances in the treatment of depression and other psychiatric diseases. This review summarises current knowledge concerning the SSRI class of drugs and discusses the importance of secondary pharmacology in the mechanism of action and effectiveness of these drugs. This area of research has shed light on the pharmacological mechanisms of SSRI therapy and has increased the therapeutic usefulness of serotonin reuptake inhibition, especially in the area of depression. Particular attention is given to the emerging importance of the SSRI ‘plus’ approach: where the serotonin reuptake receptor inhibition of a drug is supplemented by one or more other receptor interactions either by the same drug or by a combination therapy. There are many new emerging SSRI ‘plus’; drugs, which address the pharmacological and pharmacokinetic issues of current therapies and these are discussed in detail.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Serotonin; combination therapy; emerging SSRI

Document Type: Review Article

Affiliations: Department of Medicinal Chemistry, Scottish Biomedical, Number One, Kelvin Campus, West of Scotland Science Park, Glasgow, Scotland, UK, G20 0SP.

Publication date: January 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more